CNS effects of CB2 cannabinoid receptors: Beyond neuro-immuno-cannabinoid activity

Journal of Psychopharmacology

Volumn 26, Issue 1, 2012, Pages 92-103

  Onaivi, Emmanuel S ^a,b   Ishiguro, Hiroki ^b,c   Gu, Shanzhi ^d   Liu, Qing Rong ^b  

^a WILLIAM PATERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Brain; CB2 cannabinoid receptors; CNR2; neuronal and glial distribution; neuropsychiatry

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; DIZOCILPINE; ISOPROTEIN; METHAMPHETAMINE;

CENTRAL NERVOUS SYSTEM; CNR2 GENE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE PRODUCT; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MENTAL DISEASE; NEUROPSYCHIATRY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; HUMANS; NEURONS; RECEPTOR, CANNABINOID, CB2;

EID: 84863011465     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111400652     Document Type: Review

References (128)

1. Achur RN, Freeman WM, Vrana KE. Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J Neuroimmune Pharmacol. 2010 ; 5: 83-91
2. Agrawal A, Hinrichs AL, Dunn G, et al. Linkage scan for quantitative traits identifies new regions of interest for substance dependence in the Collaborative Study on the Genetics of Alcoholism (COGA) sample. Drug Alcohol Depend. 2008 ; 93: 12-20 (Pubitemid 350236585)
3. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev. 2008 ; 108: 1687-1707 (Pubitemid 351796405)
4. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987 ; 2: 1483-1486
5. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation dependent neurodegeneration. Curr Neuropharmacol. 2007 ; 5: 73-80 (Pubitemid 47019422)
6. Ashton JC, Friberg D, Darlington CL, Smith PF. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett. 2006 ; 396: 113-116 (Pubitemid 43276423)
7. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010 ; 160: 467-479
8. Baek J-H, Zheng Y, Darlington CL, et al. Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol. 2008 ; 128: 1-7
9. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr Res. 2008 ; 99: 1-6
10. Basavarajappa BS, Hungund BL. Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol Alcohol. 2005 ; 40: 15-24
11. Benito C, Nunez E, Tolon RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003 ; 23: 11136-11141 (Pubitemid 37548949)
12. Benito C, Kim WK, Chavarria I, et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci. 2005 ; 25: 2530-2536 (Pubitemid 40365164)
13. Benito C, Tolon RM, Pazos MR, et al. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2008 ; 153: 277-285
14. Berg KM, Kunins HV, Jackson JL, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med. 2008 ; 121: 406-418 (Pubitemid 351626009)
15. Bermudez-Silva FJ, Serrano A, Diaz-Molina FJ. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol. 2006 ; 531: 282-284 (Pubitemid 43202248)
16. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007 ; 565: 207-211 (Pubitemid 46782769)
17. Boyle AP, Davis S, Shulha HP, et al. High-resolution mapping and characterization of open chromatin across the genome. Cell. 2008 ; 132: 311-322 (Pubitemid 351172431)
18. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berlin). 2001 ; 156: 234-258 (Pubitemid 32705488)
19. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 ; 57: 817-820 (Pubitemid 40487928)
20. Brown SM, Wager-Miller J, Mackie K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta. 2002 ; 1576: 255-264 (Pubitemid 34655768)
21. Brusco A, Taglaiferro PA, Saez T, et al. Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann NY Acad Sci. 2008a ; 1139: 450-457
22. Brusco A, Tagliaferro P, Saez T, et al. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse. 2008b ; 62: 944-949
23. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol. 2000 ; 396: 141-149 (Pubitemid 30265571)
24. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 2009 ; 11: e3
25. Cabral GA, Raborn ES, Griffin L, et al. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008 ; 153: 240-251
26. Castro-Fornieles J, Diaz R, Goti J, et al. Prevalence and factors related to substance use among adolescents with eating disorders. Eur Addict Res. 2010 ; 16: 61-68
27. Chin CL, Tovcimak AE, Hradil VP, et al. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol. 2008 ; 153: 367-379
28. Cho H, Kim KM, Kim YK, et al. Human proline-rich nuclear receptor coregulatory protein 2 mediates an interaction between mRNA surveillance machinery and decapping complex. Mol Cell. 2009 ; 33: 75-86
29. Cichon S, Craddock N, Daly M, et al. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry. 2009 ; 166: 540-556
30. De Filippis D, Steardo A, D'Amico A, et al. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection. Sci World J. 2009 ; 9: 229-235
31. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003 ; 2: 5
32. Duan J, Sanders AR, Gejman PV. Genome-wide approaches to schizophrenia. Brain Res Bull. 2010 ; 83: 93-102
33. Edenberg HJ, Koller DL, Xuei X, et al. Genome-wide association study of alcohol dependence implicates a region on chromosome 11. Alcohol Clin Exp Res. 2010 ; 34: 840-852
34. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, et al. Distinctive pattern of cannabinoid type II (CB2) expression in adult and pediatric brain tumors. Brain Res. 2007 ; 1137: 161-169 (Pubitemid 46240056)
35. Fernandez-Ruiz J, Romero J, Velasco G, et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival. Trends Pharmacol Sci. 2006 ; 28: 39-45
36. Fernandez-Ruiz J, Pazo MR, Garcia-Arencibia X, et al. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol. 2008 ; 286: S91 - S96
37. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 ; 232: 54-61
38. Garcia-Gutierrez MS, Manzanares J. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol. 2010 ; 00: 1-00
39. Garcia-Gutierrez MS, Perez-Ortiz JM, Gutierrez-Adan A, Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol. 2010 ; 160: 1773-1784
40. GhoseH (2009) Cannabinoid controversy. The Scientist. Retrieved from http://www.the-scientist.com/news/display/55969/ (accessed 26 January 2011).
41. Golech SA, McCarron RM, Chen Y, et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Mol Br Res. 2004 ; 132: 87-92 (Pubitemid 39531355)
42. Gong J-P, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006 ; 1071: 10-23 (Pubitemid 43255471)
43. Griffin G, Wray EJ, Tao Q, et al. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for CB2 receptor absence in the rat central nervous system. Eur J Pharmacol. 1999 ; 377: 117-125 (Pubitemid 29322766)
44. Grimsey NL, Goodfellow CE, Scotter EL, et al. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal. J Neurosci Methods. 2008 ; 171: 78-86
45. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005 ; 62: 1097-1106 (Pubitemid 41396935)
46. Hill EL, Gallopin T, Ferezou I, et al. Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol. 2007 ; 97: 2580-2589 (Pubitemid 46557693)
47. Hoffman HS, Ison JR. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev. 1980 ; 87: 175-189
48. Holliday EG, Nyholt DR, Tirupati S, et al. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. Am J Psychiatry. 2009 ; 166: 206-215
49. Holmans PA, Riley B, Pulver AE, et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry. 2009 ; 14: 786-795
50. Ibrahim M, Deng H, Zvonok K, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the brain. Proc Natl Acad Sci. 2003 ; 100: 10529-10533 (Pubitemid 37071912)
51. Ishiguro H, Iwasaki S, Teasenfitz L, et al. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J. 2007 ; 7: 380-385 (Pubitemid 350187449)
52. Ishiguro H, Horiuchi Y, Ishikawa M, et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry. 2010a ; 67: 974-982
53. Ishiguro H, Carpio O, Horiuchi Y, et al. A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. Synapse. 2010b ; 64: 92-96
54. Jean-Gilles L, Gran B, Constantinescu CS. Interaction between cytokines, cannabinoids and the nervous system. Immunology. 2010 ; 215: 606-610
55. Jhaveri MD, Elmes SJ, Richardson D, et al. Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci. 2008 ; 27: 1722-1730 (Pubitemid 351473595)
56. Joosten M, Valk PJ, Vankan Y, et al. Phenotyping of Evi1, Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice. Virology. 2000 ; 268: 308-318 (Pubitemid 30159980)
57. Karsak M, Cohen-Solal M, Freudenberg J, et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005 ; 14: 3389-3396 (Pubitemid 41672123)
58. Koch M, Habazetti I, Dehghani F, et al. The rat pineal gland comprises an endocannabinoid system. J Pineal Res. 2008 ; 45: 351-360
59. Koethe D, Llenos IC, Dulay JR, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm. 2007 ; 114: 1055-1063 (Pubitemid 47106441)
60. Kousseff BG, Beratis NG, Strauss L, et al. Fucosidosis type 2. Pediatrics. 1976 ; 57: 205-213
61. Lanciego JL, Barroso-Chinea P, Rico AJ, et al. Expression of mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psychopharmacol. 2010 ; 25: 97-104
62. Lappalainen J, Kranzler HR, Petrakis I, et al. Confirmation and fine mapping of the chromosome 1 alcohol dependence risk locus. Mol Psychiatry. 2004 ; 9: 312-319 (Pubitemid 38496724)
63. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999 ; 10: 1665-1669 (Pubitemid 29354290)
64. Leweke FM, Giuffrida A, Koethe D, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res. 2007 ; 94: 29-36 (Pubitemid 47031599)
65. Li CY, Zhang Y, Wang Z, et al. A human-specific de novo protein-coding gene associated with human brain functions. PLoS Comput Biol. 2010 ; 6: e1000734
66. Lind PA, Macgregor S, Vink JM, et al. A genomewide association study of nicotine and alcohol dependence in Australian and Dutch populations. Twin Res Hum Genet. 2010 ; 13: 10-29
67. Liu QR, Pan CH, Hishimoto A, et al. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav. 2009 ; 8: 519-330
68. Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology. 2006 ; 31: 795-803
69. Lopez EM, Tagliaferro P, Onaivi ES, Lopez-Costa JJ. Distribution of CB2 cannabinoid receptor in adult retina. Synapse. 2010 ;:
70. Lunn CA, Reich E-P, Fine JS, et al. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol. 2008 ; 153: 226-239
71. Malik P, Gasser RW, Kemmler G, et al. Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res. 2009 ; 33: 375-381
72. Marriot KS, Huffman JW. Recent advances in the development of selective ligands for cannabinoid CB(2) receptor. Curr Top Med Chem. 2008 ; 8: 187-204 (Pubitemid 351795769)
73. McPartland JM, Matias I, Di Marzo V, et al. Evolutionary origins of the endocannabinoid system. Gene. 2006 ; 370: 64-74 (Pubitemid 43375901)
74. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008 ; 192: 306-307 (Pubitemid 351692406)
75. Morgan NH, Stanford IM, Woodhall GL. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology. 2009 ; 57: 356-368
76. Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006 ; 10: 131-148
77. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993 ; 365: 61-65 (Pubitemid 23305569)
78. Murikinati S, Juttler E, Keinert T, et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2010 ; 24: 788-798
79. Nagarkatti P, Pandey R, Rieder SA, et al. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009 ; 1: 1333-1349
80. Nunez E, Benito C, Pazos MR, et al. Cannabinoid CB2 receptors are expressed by perivascular microglia cells in the human brain: an immunohistochemical study. Synapse. 2004 ; 53: 208-213 (Pubitemid 39045539)
81. Onaivi ES. Neuropsychopharmacological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology. 2006 ; 54: 231-246
82. Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol. 2009 ; 88: 335-369
83. Onaivi ES. Endocannabinoid system, pharmacogenomics and response to therapy. Pharmacogenomics. 2010 ; 11: 907-910
84. Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci. 2006a ; 1074: 514-536 (Pubitemid 44532857)
85. Onaivi ES, Ishiguro H, Patel S, et al Marijuana and Cannabinoid Research: Methods and Protocols. Onaivi ES, ed. Totowa: Humana Press Inc ; 2006b: 291-298.
86. Onaivi ES, Ishiguro H, Gong J-P, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann NY Acad Sci. 2008a ; 1130: 434-449
87. Onaivi ES, Carpio O, Ishiguro H, et al. Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann NY Acad Sci. 2008b ; 1139: 426-433
88. Ong WY, Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate spinal cord. J Neurocytol. 1999 ; 28: 39-45 (Pubitemid 30040768)
89. Ortega-Alvaro A, Aracil-Fernandez A, Garcia-Gutierrez MS, et al. Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Soc Neuro Abst. 2010 ; 471: 11
90. Palazuelos J, Aguado T, Egia A, et al. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006 ; 20: E1773 - E1779
91. Paldy E, Bereczki E, Santha M, et al. CB2 cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB2 receptor in pain. Neurochem Int. 2008 ; 53: 309-316
92. Paldyova E, Bereczki E, Santha M, et al. Noladin ether, a putative endocannabinoid, inhibits mu-opoid receptor activation via CB2 cannabinoid receptors. Neurochem Int. 2008 ; 52: 321-328 (Pubitemid 350235710)
93. Patel KD, Davison JS, Pittman QJ, et al. Cannabinoid CB2 receptors in health and disease. Curr Med Chem. 2010 ; 17: 1394-1410
94. Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res. 2009 ; 204: 313-321
95. Peters EN, Hughes JR. Daily marijuana users with past alcohol problems increase alcohol consumption during marijuana abstinence. Drug Alcohol Depend. 2010 ; 106: 111-118
96. Piontkivska H, Yang MQ, Larkin DM, et al. Cross-species mapping of bidirectional promoters enables prediction of unannotated 5' UTRs and identification of species-specific transcripts. BMC Genomics. 2009 ; 10: 189
97. Plackett TP, Kovacs EJ. Acute models of ethanol exposure to mice. Methods Mol Biol. 2008 ; 447: 3-9
98. Renn JH, Yang NP, Chueh CM, Lin CY, Lan TH, Chou P. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord. 2009 ; 10: 1
99. Rivers JR, Ashton JC. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. Cent Nerv Syst Agents Med Chem. 2010 ; 10: 47-64
100. Roche M, Finn DP. Brain CB2 receptors: implications for neuropsychiatric disorders. Pharmaceuticals. 2010 ; 3: 2517-2553
101. Rodriguez-Martin I, Herrero-Turrion MJ, Marron Fdez de Velasco E, Gonzalez-Sarmiento R, Rodriguez RE. Characterization of two duplicate zebrafish Cb2-like cannabinoid receptors. Gene. 2007 ; 389: 36-44 (Pubitemid 46107774)
102. Ruiz-Valdepenas L, Benito C, Tolon RM, et al. The endocannabinoid system and amyloid-related diseases. Exp Neurol. 2010 ; 224: 66-73
103. Sammarco CL. A case study: identifying alcohol abuse in multiple sclerosis. J Neurosci Nurs. 2007 ; 39: 373-376
104. Sampson HW. Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health. 2002 ; 26: 292-298
105. Sartor CE, Grant JD, Bucholz KK, et al. Common genetic contributions to alcohol and cannabis use and dependence symptomatology. Alcohol Clin Exp Res. 2010 ; 34: 545-554
106. Sheng WS, Hu S, Min X, et al. Synthetic cannabinoid WIN55212-2 inhibits generation of inflammatory mediators by IL-IB-stimulated human astrocytes. Glia. 2005 ; 49: 211-219 (Pubitemid 40188500)
107. Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol. 2005 ; 78: 231-238 (Pubitemid 40979962)
108. Sobieszczuk DF, Poliakov A, Xu Q, Wilkinson DG. A feedback loop mediated by degradation of an inhibitor is required to initiate neuronal differentiation. Genes Dev. 2010 ; 242: 206-218
109. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006 ; 27: 71-80 (Pubitemid 44528264)
110. Suarez J, Bermudez-Silva FJ, Mackie K, et al. Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol. 2008 ; 509: 400-421
111. Suarez J, Llorente R, Romero-Zerbo SY, et al. Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB1 and CB2 cannabinoid receptors of neonatal rats. Hippocampus. 2009 ; 19: 623-632
112. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 ; 63: 1325-1335 (Pubitemid 44878517)
113. Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunology. 2010 ; 215: 588-597
114. Ternianov A, Perez-Ortiz JM, Solesio ME, et al. Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol Aging. 2010 ; 00: 1-00
115. Treutlein J, Cichon S, Ridinger M, et al. Genome-wide association study of alcohol dependence. Arch Gen Psychiatry. 2009 ; 66: 773-784
116. Uhl GR, Ishiguro H, Onaivi ES, et al Marijuana and Cannabinoid Research: Methods and Protocols. Onaivi ES, ed. Totowa: Humana Press Inc ; 2006: 1-17.
117. Valk PJ, Hol S, Vankan Y, et al. The genes encoding the peripheral cannabinoid receptor and alpha-L-fucosidase are located near a newly identified common virus integration site, Evi11. J Virol. 1997 ; 71: 6796-6804 (Pubitemid 27355340)
118. Valk PJ, Vankan Y, Joosten M, et al. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. J Virol. 1999 ; 73: 3595-3602 (Pubitemid 29189799)
119. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005 ; 310: 329-332 (Pubitemid 41457202)
120. Vinod KY, Hungund BL. Endocannabinoid lipids and mediated system: implication for alcoholism and neuropsychiatric disorders. Life Sci. 2005 ; 77: 1569-1583 (Pubitemid 41073653)
121. Viscomi MT, Oddi S, Latini L, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the P13K/Akt pathway. J Neurosci. 2009 ; 29: 4564-4570
122. Ward RJ, Colivicchi MA, Allen R, et al. Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content. J Neurochem. 2009 ; 111: 1119-1128
123. Xi Z-X, Spiller K, Gardner EL. Cannabinoid CB1 and CB2 receptors modulate brainreward function in opposite directions in rats. Soc Neuro Abst. 2009 ; 449: 13
124. Yamaguchi F, Macrae AD, Brenner S. Molecular cloning of two cannabinoid type 1-like receptor genes from the puffer fish Fugu rubribes. Genomics. 1996 ; 35: 603-605 (Pubitemid 26270032)
125. Yamaguchi-Kabata Y, Nakazono K, Takahashi A, et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet. 2008 ; 83: 445-456
126. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002 ; 325: 1199
127. Zhang J, Feuk L, Duggan GE, Khaja R, Scherer SW. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. Cytogenet Genome Res. 2006 ; 115: 205-214 (Pubitemid 44832022)
128. Zhou D, Shen R, Ye JJ, et al. Nuclear receptor coactivator PNRC2 regulates energy expenditure and adiposity. J Biol Chem. 2008 ; 283: 541-553